Zealand Pharma A/S (CPH:ZEAL)
211.40
-1.30 (-0.61%)
Nov 20, 2026, 11:00 AM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 4.00M DKK in the quarter ending September 30, 2026, a decrease of -92.00%. This brings the company's total for the last twelve months to 4.60B, down -49.78% year-over-year. In the year 2025, Zealand Pharma had annual revenue of 9.21B with 14,598.86% growth. That makes Zealand Pharma the 9,576th largest company in the world by revenue and 42nd in Denmark.
Revenue (ttm)
4.60B
Revenue Growth
-49.78%
P/S Ratio
3.09
Revenue / Employee
7.60M
Employees
605
Market Cap
14.13B
Revenue by Geography
- Switzerland 9.18B 99.6%
- Denmark 34.90M 0.4%
Fiscal year ended Dec 31, 2025 See the full Zealand Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.21B | 9.15B | 14,598.86% |
| Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
| Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
| Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
| Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
| Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
| Dec 31, 2019 | 41.33M | 3.36M | 8.84% |
| Dec 31, 2018 | 37.98M | -98.35M | -72.14% |
| Dec 31, 2017 | 136.32M | -94.54M | -40.95% |
| Dec 31, 2016 | 230.86M | 43.19M | 23.01% |
| Dec 31, 2015 | 187.68M | 33.90M | 22.05% |
| Dec 31, 2014 | 153.77M | 147.20M | 2,239.11% |
| Dec 31, 2013 | 6.57M | -216.99M | -97.06% |
| Dec 31, 2012 | 223.57M | 81.28M | 57.13% |
| Dec 31, 2011 | 142.28M | 54.93M | 62.88% |
| Dec 31, 2010 | 87.36M | 62.04M | 245.03% |
| Dec 31, 2009 | 25.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 333.65B |
| Coloplast | 28.94B |
| Genmab | 28.27B |
| Demant | 24.63B |
| GN Store Nord | 16.52B |
| ALK-Abelló | 7.06B |
| Embla Medical | 6.56B |
| Ambu A/S | 6.47B |
Zealand Pharma News
- 1 day ago - Zealand Pharma Begins Phase 2 Trial Of Petrelintide And Enicepatide For Weight Management - Nasdaq
- 1 day ago - Zealand Pharma initiates ZYNERGY trial - TheFly
- 3 days ago - Zealand Pharma Transcript: Jefferies Global Healthcare Conference - Transcripts
- 6 days ago - Zealand Pharma Wins EU Approval For Zeydovio To Treat Short Bowel Syndrome - Nasdaq
- 6 days ago - Zealand Pharma announces EU approval of Zeydovio for SBS - TheFly
- 7 days ago - Zealand Pharma Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - Zealand Pharma Quarterly report: Q3 2026 - Filings
- 7 days ago - Zealand Pharma Slides: Q3 2026 - Filings